Aurinia Q4 2022 net revenue $28.4M (+21% YoY); FY net revenue $134.0M (+194% YoY); net loss $0.18/share

Aurinia Pharmaceuticals Inc.

2022-FY EPS reported -$0.76 revenue$134,030,000

Q4 2022 net product revenue $28.3M; FY 2022 net product revenue $103.5M.
Net loss Q4 $26.0M ($0.18/share); FY net loss $108.2M ($0.76/share).
Cash, equivalents and investments $389.4M at Dec 31, 2022.
FY 2023 net product revenue guidance reiterated at $120-140M.
Approx. 1,525 patients on LUPKYNIS therapy at year-end; 274 PSFs secured through Feb 24, 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Aurinia Pharmaceuticals Inc. reported the quarter and year ended December 31, 2022 results: revenue $28.4 million. Guidance reaffirmed.

Period: the quarter and year ended December 31, 2022
Revenue: $28.4 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

filing. --- EX-99.1 (EX-99.1 PRESS RELEASE) --- PRESS RELEASE Document Exhibit 99.1 AURINIA REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS AND COMPANY UPDATES $28.4 million in total net revenue for the fourth quarter 2022, a 21% increase over fourth quarter 2021 and $134.0 million for full year 2022, a 194% increase over 2021 Cash, cash equivalents,

View on SEC.gov

35 earnings releases filed in the last 30 days. Browse all earnings releases →

Aurinia Pharmaceuticals Inc. filing history →

Source: SEC EDGAR

accession 0001628280-23-005333

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.